From Yahoo Finance: 2025-05-27 09:08:00

Carillon Tower Advisers released its Q1 2025 investor letter, noting a significant drop in small-cap stocks with the Russell 2000 Growth Index down 11.12%. Real estate, up 1.76%, outperformed all sectors, with consumer staples rising by 0.67%. Vaxcyte, Inc. (NASDAQ: PCVX) saw a one-month return of -1.09%, closing at $32.54 per share on May 23, 2025.

In its investor letter, Carillon Eagle Small Cap Growth Fund highlighted Vaxcyte, Inc. (NASDAQ: PCVX), a biotechnology vaccine company. Vaxcyte is developing vaccines for bacterial infectious diseases, with a one-month return of -1.09% and shares losing 52.68% over the last 52 weeks.

Carillon Eagle Small Cap Growth Fund noted in its Q1 2025 letter that Vaxcyte, Inc. (NASDAQ: PCVX) is focused on developing VAX24/VAX-31 for preventing pneumococcal disease. Phase 2 trial results for VAX-24 showed promise, leading to phase 3 trials despite concerns over a FDA leader’s resignation causing a stock selloff.



Read more at Yahoo Finance: Here’s Why Vaxcyte (PCVX) Sold Off in Q1